title: Antihistaminic drug olopatadine downmodulates CCL17/TARC production by keratinocytes and Langerhans cells.
authors: Kazunari
authors: K
authors: Sugita
authors: Miwa
authors: M
authors: Kobayashi
authors: Tomoko
authors: T
authors: Mori
authors: Kenji
authors: K
authors: Kabashima
authors: Motonobu
authors: M
authors: Nakamura
authors: Yoshiki
authors: Y
authors: Tokura
mesh_terms: D000818:Animals; D002460:Cell Line; D054414:Chemokine CCL17 / Q000096:biosynthesis*; D003990:Dibenzoxepins / Q000494:pharmacology*; D015536:Down-Regulation / Q000187:drug effects; D039563:Histamine H1 Antagonists, Non-Sedating / Q000494:pharmacology*; D006801:Humans; D066298:In Vitro Techniques; D007371:Interferon-gamma / Q000494:pharmacology; D015603:Keratinocytes / Q000187:drug effects* / Q000276:immunology*; D007801:Langerhans Cells / Q000187:drug effects* / Q000276:immunology*; D051379:Mice; D008807:Mice, Inbred BALB C; D000069605:Olopatadine Hydrochloride; D011994:Recombinant Proteins; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology
chemical_list: C106230:CCL17 protein, human; C499538:Ccl17 protein, mouse; D054414:Chemokine CCL17; D003990:Dibenzoxepins; D039563:Histamine H1 Antagonists, Non-Sedating; D011994:Recombinant Proteins; D014409:Tumor Necrosis Factor-alpha; D000069605:Olopatadine Hydrochloride; D007371:Interferon-gamma